Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model

Despite the availability of recently developed chemotherapy regimens, survival times for pancreatic cancer patients remain poor. These patients also respond poorly to immune checkpoint blockade therapies (anti-CTLA-4, anti-PD-L1, anti-PD-1), which suggests the presence of additional immunosuppressiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Luheshi, Nadia M., Coates-Ulrichsen, Jane, Harper, James, Mullins, Stefanie, Sulikowski, Michal G., Martin, Philip, Brown, Lee, Lewis, Arthur, Davies, Gareth, Morrow, Michelle, Wilkinson, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951305/
https://www.ncbi.nlm.nih.gov/pubmed/26918344
http://dx.doi.org/10.18632/oncotarget.7610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951305/
https://www.ncbi.nlm.nih.gov/pubmed/26918344
http://dx.doi.org/10.18632/oncotarget.7610

Ejemplares similares